NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Standard Biotools Inc. LAB
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$85.3M
▼ 6.2% vs FY2024
EPS · FY25
$-0.20
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-16.7%
Net margin · FY25
-87.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 85.3M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 88 cents on every revenue dollar this year.
Per share
USD -0.20
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-16.7%
Return on equity, FY2025
ROE
Operating margin-129.2%
Net margin-87.8%
Return on assets-12.7%
Each USD of equity lost 17 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -531,000.00
Share of profit-0.0%
Consecutive raises—
Growth
−9.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−4.5%
−9.2%
−2.9%
+6.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.39B
Shares outstanding, FY2025
Change, 5 years+62.6%
Change, 10 years+210.8%
The share count grew 63% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 567.8M
total assets, end of FY2025
Total assetsUSD 567.8M
EquityUSD 424.3M
CashUSD 120.9M
Current ratio4.19×
Equity funds 75% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.1
−0.1
−0.1
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.20
−0.52
−0.94
−2.43
−0.78
−0.74
−0.97
−1.49
−1.84
−2.62
−1.86
−1.90
−0.65
−0.86
−1.81
−8.94
−11.02
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−16.7
−85.8
·
−2895.8
−50.7
−36.2
−57.4
−114.5
−143.8
−90.4
−40.2
−42.8
−16.8
−24.1
·
·
·
Shares out B
0.39
0.38
0.08
0.08
0.08
0.07
0.07
0.05
0.04
0.03
0.03
0.03
0.03
0.03
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
55 of 56
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed